Christian Schindlbeck
Overview
Explore the profile of Christian Schindlbeck including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
38
Citations
1638
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Tzschaschel M, Friedl T, Schochter F, Schutze S, Polasik A, Fehm T, et al.
Clin Breast Cancer
. 2023 Jun;
23(6):e345-e353.
PMID: 37336651
Background: Obesity and the presence of circulating tumor cells (CTCs) before and/or after chemotherapy are associated with poor outcome in breast cancer (BC) patients. The activation of oncogenic pathways in...
2.
Kuemmel S, Heil J, Bruzas S, Breit E, Schindowski D, Harrach H, et al.
JAMA Surg
. 2023 Jun;
158(8):807-815.
PMID: 37285140
Importance: The increasing use of neoadjuvant systemic therapy (NST) has led to substantial pathological complete response rates in patients with initially node-positive, early breast cancer, thereby questioning the need for...
3.
Heublein S, Egger M, Zhu J, Berger L, Mayr D, Schindlbeck C, et al.
Breast Cancer Res Treat
. 2019 Dec;
179(3):643-652.
PMID: 31828591
Purpose: The TF (Thomsen-Friedenreich, CD176, Galβ1-3GalNAc) carbohydrate moiety is known as a specific oncofetal carbohydrate epitope present in fetal and neoplastic tissue as well as in stem cells. TF was...
4.
Trapp E, Janni W, Schindlbeck C, Juckstock J, Andergassen U, DeGregorio A, et al.
J Natl Cancer Inst
. 2019 Jun;
111(11):1234-1235.
PMID: 31187135
No abstract available.
5.
Trapp E, Janni W, Schindlbeck C, Juckstock J, Andergassen U, de Gregorio A, et al.
J Natl Cancer Inst
. 2018 Oct;
111(4):380-387.
PMID: 30312434
Background: The prognostic relevance of circulating tumor cells (CTCs) at the time of primary diagnosis has been well established. However, little information is available regarding their prognostic relevance to follow-up...
6.
Schochter F, Rack B, Tzschaschel M, Polasik A, Andergassen U, Trapp E, et al.
Oncol Res Treat
. 2018 Mar;
41(3):93-98.
PMID: 29490302
Background: Optimal choice and sequence of endocrine treatment following adjuvant chemotherapy in postmenopausal early breast cancer patients are still under discussion and treatment stratification factors are missing. Patients And Methods:...
7.
Holzel D, Eckel R, Bauerfeind I, Baier B, Beck T, Braun M, et al.
J Cancer Res Clin Oncol
. 2017 Apr;
143(9):1701-1712.
PMID: 28429102
Purpose: Systemic therapies (ATHs) in early breast cancer have improved the survival of breast cancer (BC) patients in recent decades. The magnitude of the changes in overall, metastasis-free (MFS) and...
8.
Holzel D, Eckel R, Bauerfeind I, Baier B, Beck T, Braun M, et al.
J Cancer Res Clin Oncol
. 2016 Nov;
143(3):509-519.
PMID: 27853869
Background: De novo stage IV breast cancer patients (BC) depict a clinical picture not influenced by adjuvant therapy. Therefore, the time-dependent impact of changes in diagnostics and treatments on progression...
9.
Jueckstock J, Burkhardt N, Kuhn C, Blankenstein T, Mahner S, Schindlbeck C, et al.
Anticancer Res
. 2016 Apr;
36(5):2153-9.
PMID: 27127117
Background/aim: Activins are dimeric glycoproteins that play a significant role in reproduction and in endocrine-active tumors. The aim of this study was to evaluate the potential correlation between the concentration...
10.
Rack B, Zombirt E, Trapp E, Juckstock J, Andergassen U, Neugebauer J, et al.
Oncology
. 2016 Mar;
90(4):232-8.
PMID: 26937631
Objective: The aim of this study was to measure the human epidermal growth factor receptor 2 (HER2) status of disseminated tumor cells (DTCs) from bone marrow (BM) aspirates and to...